Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This information isn't necessarily accurate either. Saying CVD is based on diet, exercise, etc. Yes, in most cases it can be, but not all the time. People are having heart attacks much younger each and every year. Here are a couple of outliers from last year specifically.
100% blockage on a 26 year old NFL athlete:
https://www.yahoo.com/entertainment/raiders-nick-o-leary-recovering-from-heart-attack-surgery-for-100-percent-blockage-154857116.html
Another 27 year old college athlete, and Pro Basketball Player (EU):
https://www.tallahassee.com/story/sports/college/fsu/mensbasketball/2020/08/07/florida-state-fsu-basketball-alum-michael-ojo-seminoles-death-nigeria-center-leonard-hamilton/3317263001/
Raf, he's creating his own definition of pandemic.
Pandemic definition - (of a disease) prevalent over a whole country or the world.
That's it. No requirements for being contagious. By the definition of pandemic, CVD SHOULD be considered one.
2 times more people died of CVD than Covid.
https://jamanetwork.com/journals/jama/fullarticle/2778234
https://usafacts.org/articles/top-causes-death-united-states-heart-disease-cancer-and-covid-19/
I will take facts over feelings and false interpretations every day.
Only some of this information is accurate. Dr.'s were having to jump through hoops well before generic entry. Once expanded label happened, it was as if insurance companies tightened up coverage on Vascepa. It was easier to get off-label coverage before expanded label. Try to get off-label coverage right now. See what happens.
Also, sales stalled beginning Dec 2019. The average weekly script in 2020 was 85.5k. What changed Jan 1st? Expanded label coverage.
check your twitter DM.
You might want to read it again. Because the letter doesn't say it's being dropped for "Lipid Lowering." It doesn't give any reason.
All it says is that it will no longer be covered starting May 1st. You're assuming the patient isn't prescribed V for CVD indication. The letter says nothing to differentiate the 2 labels as stated in my previous post.
Not based on letters people are receiving in the mail. Just a flat out denial of coverage. The language isn't differentiating between labels.
I understand the situation. I was explaining what the original poster was asking. You seemed confused by what he was saying, questioning "they." Just giving clarification to your question of his interpretation.
They, I believe is Hikma. I believe what he's trying to say is that Hikma is not arguing the content of the evidence presented. Hikma is more casting doubt on Marjac's character (conspiracy theorist, etc.).
That wasn't the question I asked, nor the context.
Continuing to blindly hope is not a plan. The r60 filing is a great move even if the effort is futile. A similar concerted effort should be made to remove JT at a minimum.
#4 is a Catch-22 for AMRN management. If they show support for rule 60
they have to admit their own negligence in not having caught the errors.
Then, if they ignore rule 60 they are blatantly demonstrating their lack
of fiduciary responsibility. I guess if their decision to ignore rule 60
sticks, it is probably a worse decision by JT and team. The phrase
"stupid is as stupid does" comes to mind. Sadly, seems we cannot expect
anything less from JT.
Neither one of those are correct. Thero put out weak guidance to get more free options. He said that if it wasn't for Covid they would've made 800m-900m.
Transcript from JPM. Scroll down to Q&A:
https://seekingalpha.com/article/4398656-amarin-corporation-plc-amrn-ceo-john-thero-presents-39th-annual-jpmorgan-virtual-healthcare
I don't know if it's technically missing. These were the requirements verbatim from my denial letter.
Copied directly from my insurance denial letter.
Criteria for coverage:
Tg level of 500+
OR
you must have a treated (such as taking a statin drug like atorvostatin) TG level of 135-499 AND meet one of the following:
1.) Are at least 45 years old and have cardiovascular (heart and blood vessels) disease or,
2.) are at least 50 years old and have diabetes (a condition effecting blood and sugar) AND have one of the following:
a.) are a man that is at least 55 years old or a woman that is at least 65 years old,
b.) smokes cigarettes or stopped smoking them in the past 3 months,
c.) are using a drug for high blood pressure or have high blood pressure (140 mmHg systolic or 90mmHg diastolic)
d.) have a lab test showing your HDL cholesterol level is 40 mg/dL or less for a male or 50 mg/dL or less for a female
e.) have a lab test showing your hsCRP (high sensitivity C-reactive protein) level is greater than 3 mg/dL,
f.) have a creatinine clearance lab test of more than 30mL/min but less than 60 mL/min,
g.) have retinopathy (an eye condition) or,
h.) have micro- or macro-albuminuria (the presence of a type of protein in the urine)
Nothing. I am self pay. My insurance denied Vascepa coverage due to age.
I'm paying $184/mo self pay with savings card.
You're missing the point. The average patient isn't going to pay $200+ for Vascepa. Most Vascepa scripts written after Reduce-It were off-label. Prior Auths are cutting off coverage for people who got scripts that way.
Not only does BCBS-TX have prior auth, but they've installed age limits on coverage as well.
where do you live? (city/state)
No issues here in North Dallas, TX. Got mine filled today.
LRich, You're hitting the nail right on the head here.
AMRN has refused to put a number on the US. Before and after generic launch. They've also refused to put a number on EU. The continued ambiguous talking points of "muli-billion dollar opportunity" have grown stale.
In previous dialogue with AMRN IR I've implored them to put a number on the US and EU...at least the EU. My example was HLS put out peak guidance the day they received Can approval. If they can, why not AMRN?
The response I received from AMRN IR regarding EU peak potential was, "ON REPEATED OCCASSIONS AMARIN HAS QUANTIFIED THE NUMBER OF PATIENTS IN EUROPE WHO MIGHT BENEFIT FROM VASCEPA. AMARIN HAS REFERRED TO THIS AS A POTENTIAL MULTI-BILLION DOLLAR OPPORTUNITY. UNTIL A LABEL IS APPROVED IN EUROPE AND REIMBURSEMENT FOR THE PRODUCT IS DEFINED, IT IS PREMATURE TO BE MORE SPECIFIC."
We all know this to be a lie. Why is it a lie? Based on offers for BO and partnership AMRN determined that a GIA strategy was in their best interest. How can they determine that? THEY PUT A NUMBER ON THE EU MARKET! Why that number is a secret to anyone outside of the C-suite, I'll never know. But they've come up with a number, and that worst case scenario number told them that this was the best route. Any talking points the contrary is a flat out lie.
I don't think so. I received a response from IR last week. But the email doesn't have a signature. I have no idea who responded from the IR email.
Raf,
a lot of states have a mandatory substitution:
https://www.mymatrixx.com/wp-content/uploads/2017/04/Mandatory-Generic-Chart-as-of-March-2017.pdf
BCBS-TX has prior authorization. Also added a minimum age limit.
Apathetic shareholders haven't solved anything, either. But keep doing the same thing over and over expecting a different result.
Also, show me where I called him
childish names
Unfortunately for your attempt to discredit my opinion. I'm a multi-year shareholder with a large six figure position.
That's hilarious... I'm not worried about the opinion of someone who is DIRECTLY RESPONSIBLE for the loss of 80% of the company's value.... You get fired for that in the real world. You don't get more free options.
Too many JT apologists. If most on this board had a better understanding of operations management and sales/marketing they wouldn't be making excuses for JT. Unfortunately, most here haven't run their own businesses. If they had, they would see through JT and the AMRN BOD and would be utterly furious.
Visited my pcp today. He upped my blood pressure medicine as a precaution in case I catch Covid. Said people with Covid, their bp goes sky high. It happened to him, personally, 3 weeks ago. He's 55, works out 6 times a week and eats extremely healthy. Had him in rough shape for 3 solid days.
You're wrong here. Both of you. It's not the sales rep's place to explain away Thero and Amarin management's failure. It's his job to spread the word of Vascepa and get you to write scripts.
It's unprofessional of Thero and AMRN to have not addressed the situation publicly, already. The coward hides in Biden's basement while sales reps have to answer for his screw ups. This company needs a real leader.
Not at all. The only way to get through to these idiots is by force. They clearly don't care about shareholders. If they did care, they wouldn't treat us like mushrooms-leaving us in the dark. Also, the excuse of, "The generics are listening to everything we do," is just that, an excuse. A bad one. There is ZERO justification for keeping shareholders in the dark. They've done this ALL year. The shareholders didn't make the terrible decisions management did, but we're definitely the ones feeling the repercussions. We have a right to know the plan moving forward.
Most of what you're saying is preaching to the choir. However, where we disagree is that a sale needs to happen BEFORE EMA approval, not after. For the same exact value reasons you've listed.
If you don't acknowledge it, it never happened.
This is right on point. A hard truth many on this board refuse to admit, too.
You’ve clearly NEVER served.
The military’s fix for everything is 800mg Motrin and to drink water.
How do you compare Lipitor year one to Amarin this year? This isn’t Amarin’s first year selling Vascepa.
Amarin made $430mm last year. On pace for $600mm this year. $170mm increase.
Lipitor made $700mm in a real first year. They didn’t have refills carry over from the previous year, either.
We won’t be off by much? How did you come up with that? $170mm vs $700mm- it’s not even close.